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Abstract
Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-a) was the treatment of choice in chronic myeloid
leukemia (CML). Curiously, some IFN-a treated patients were able to discontinue therapy without disease progression. The
aim of this project was to study the immunomodulatory effects of IFN-a in CML patients in prolonged remission and isolate
biological markers predicting response. Due to rarity of patients on IFN-a monotherapy, a relatively small cohort of patients
still on treatment (IFN-ON, n=10, median therapy duration 11.8 years) or had discontinued IFN-a therapy but remained in
remission for .2 years (IFN-OFF, n=9) were studied. The lymphocyte immunophenotype was analyzed with a
comprehensive flow cytometry panel and plasma cytokine levels were measured with multiplex bead-based assay. In
addition, the clonality status of different lymphocyte subpopulations was analyzed by TCR c/d rearrangement assay. Median
NK-cell absolute number and proportion from lymphocytes in blood was higher in IFN-OFF patients as compared to IFN-ON
patients or controls (0.42, 0.19, 0.21610
9/L; 26%, 12%, 11%, respectively, p,0.001). The proportion of CD8+ T-cells was
significantly increased in both patient groups and a larger proportion of T-cells expressed CD45RO. Most (95%) patients had
significant numbers of oligoclonal lymphocytes characterized by T-cell receptor c/d rearrangements. Strikingly, in the
majority of patients (79%) a distinct clonal Vc9 gene rearrangement was observed residing in cd
+ T-cell population. Similar
unique clonality pattern was not observed in TKI treated CML patients. Plasma eotaxin and MCP-1 cytokines were
significantly increased in IFN-OFF patients. Despite the limited number of patients, our data indicates that IFN-a treated CML
patients in remission have increased numbers of NK-cells and clonal cd
+ T-cells and a unique plasma cytokine profile. These
factors may relate to anti-leukemic effects of IFN-a in this specific group of patients and account for prolonged therapy
responses even after drug discontinuation.
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Introduction
The Philadelphia chromosome (Ph) resulting from the reciprocal
translocation between chromosomes 9 and 22 is the hallmark of
chronic myeloid leukemia (CML). The t(9;22) translocation leads to
the formation of the BCR-ABL oncogene and produces a fusion
protein which has an autonomous tyrosine kinase activity [1]. The
discovery of tyrosine kinase inhibitors (TKIs) has dramatically
improved the survival of CML patients [2,3,4]. However, they are
notconsidered tobecurative sincetheydonoteliminateallPh
+cells
and discontinuation of the therapy often leads to disease relapse [5].
Before the TKI therapy era, interferon alpha (IFN-a) was the
treatment of choice in CML [6]. Only a small proportion of
patients (10–20%) achieved a complete cytogenetic remission
(CCyR), but these patients had a prolonged survival [7,8]. Recent
multicenter studies have shown that combination of IFN-a with
the TKI imatinib improves the therapy outcome [9,10,11]. Also
studies evaluating the successful treatment discontinuation in
CML have suggested that IFN-a therapy may improve the
possibility to stop TKI therapy [5,12]. The mechanism of action of
IFN-a therapy is incompletely understood; the drug exerts both
direct cytostatic and immunomodulatory effects on leukemic cells.
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23022It can down-regulate the expression of the BCR-ABL1 gene, and
activate several transcriptional factors that regulate cell prolifer-
ation, maturation, and apoptosis [13,14,15,16,17]. IFN-a can also
induce recognition and elimination of CML cells by the immune
system [18,19,20,21]. Recent studies have also suggested that it
can promote the cycling of normal quiescent hematopoietic stem
cells [22]. If similar mechanism of action occurs with dormant
leukemic stem cells (LSCs), IFN-a treatment may induce their
cycling and thereby expose LSCs to the effects of TKIs and
chemotherapeutic agents.
The most striking evidence of the immunomodulatory effects
of IFN-a comes from studies which have shown that a
significant proportion of IFN-a treated patients in prolonged
CCyR were able to discontinue treatment without imminent
disease relapse. However, many of these patients still have
detectable minimal residual disease [23,24]. It would be
important to understand the mechanisms of drug-induced cure
and to assess which factors are important in the maintenance of
residual tumor cell dormancy.
The aim of this project was to study the immunomodulatory
effects of IFN-a treatment in two unique CML patient
populations: (1) patients in prolonged remission during IFN-a
monotherapy and (2) patients in prolonged remission after IFN-a
monotherapy discontinuation. Such patients are very rare
nowadays as TKI therapy has replaced IFN-a in the treatment
of CML and therefore, the sample size in this study is limited.
However, also with a small number of patients we were able to
find distinct changes in the immunoprofile of IFN-a treated
patients and these findings should be confirmed in upcoming




The study was conducted in accordance with the principles of
the Helsinki declaration and was approved by the Helsinki
University Central Hospital and University Hospital Olomouc
Ethics Committees. Written informed consents were obtained
from all patients and healthy controls prior to sample collection.
Study patients and samples
All CML treating physicians in Finland, Czech and Slovak
republic were contacted and we were able to identify 19 chronic
phase CML patients treated with IFN-a monotherapy. None of
the patients were previously treated with TKI therapy. 10 patients
were using IFN-a at the time of sampling (age at sampling 33–74
years; median time for treatment 142 months, range 63–231),
while 9 patients had discontinued the therapy (age at sampling 45–
68 years; median time on treatment 93 months, range 57–132) and
stayed in remission at least 2 years (median time without treatment
53 months, range 24–96 months). The reasons for IFN-a
discontinuation were request of the patient and/or side effects of
the therapy. The majority of the patients have been in CMR for a
long period and only in some patients BCR-ABL fusion gene was
detectable, but there was the plateau in the transcript level. More
detailed patient characteristics are presented in table 1. From 7
patients (4 IFN-ON and 3 IFN-OFF) a follow-up sample (time
between samples 15–31 months) was available. As controls we
included 4 patients with myeloproliferative neoplasms (MPN)
treated with IFN-a (3 patients with essential trombocythemia and
one patient with polycythemia vera; age at sampling 26–62 years;
median time for therapy 43 months, range 25–108) and 43 healthy
volunteers (age at sampling 20–64 years).
Fresh peripheral blood (PB) samples were collected from all
patients and healthy controls. Mononuclear cells (MNCs) were
separated by Ficoll gradient centrifugation (GE healthcare,
Buckinghamshire, UK).
Blood cell counts were obtained from routine laboratory tests.
Molecular genetic analysis of BCR-ABL transcripts was performed
with real-time quantitative PCR in quality-controlled laboratories.
The cytogenetic response was assessed using conventional G-
banding technique.
Immunophenotyping of PB lymphocytes and leukocyte
subpopulations
Immunophenotyping was done with a 6-color flow cytometry
panel including antibodies against the following antigens: CD3,
CD4, CD8, CD16/56, CD19, CD45, CD57, CD45RA,
CD45RO, T-cell receptor (TCR)-a/b, TCR-c/d, CCR2,
CCR3, and Vc9 with isotype controls. Regulatory T-cells (Treg)
were analyzed with CD3, CD4, CD25, and FOXP3 (clone
PCH101, eBioscience, San Diego, CA, USA) antibodies.
From the lymphocyte population, proportions of T-, B-, NKT-
like (T-cells with CD16/56 NK-cell marker) and NK-cells were









+ T-cells, proportions of CD4
+ helper and CD8
+ cytotoxic
T-cell subpopulations were identified. Also TCR status, CD45RA,
and CD45RO cell surface antigens were analyzed from T-cells
and CD4
+ and CD8
+ subtypes. Absolute numbers of defined cell
types were counted from PB cell populations using relative
numbers and total white blood cell counts. All antibodies were
purchased from BD Biosciences (San Diego, CA, USA) if not
otherwise mentioned. Cells were stained according to manufac-
turer’s recommendations. 1–5610
5 cells were analyzed with
FACSCanto (Beckton Dickinson, San Jose, CA, USA). The data
analysis was done with FACSDiva software (version 6.0, BD
Biosciences).
Analysis of HLA-A2 and measurement of PR1 specific
T-cells
10 patients (table 1) were analyzed for their HLA-A2 expression
with OLERUP SSP
TM HLA-kit (Olerup SSP AB, Saltsjobaden,
Sweden) for locus A according to the manufacturer’s recommen-
dations. Approximately 5 million PB MNC from HLA-A*0201
positive patients were stained with the following antibodies: CD3,
CD4, CD8, and PR1 iTAg
TM MHC Class I human Tetramer
(Beckman Coulter, Brea, CA, USA). 5610
5 CD8
+ cells were
analyzed with FACSAria and the data analysis was done with
FACSDiva software.




Approximately 10 million mononuclear cells (MNCs) from 10
CML patients, 4 MPN patients, and 3 healthy volunteers (mean
age 45) were stained with antibodies against the following antigens:
CD45, CD3, TCR a/b, and TCR c/d. Lymphocyte populations





+. All antibodies were purchased from BD and sorting of
cells was performed on FACSAria. Purity of the sorted fractions
was confirmed with flow cytometry to be close to 100%.
DNA extraction
Genomic DNA was isolated from frozen, or sorted PB MNCs
by Genomic DNA from Tissue; NucleoSpinH Tissue or Tissue XS
(Machery-Nagel, Du ¨ren, Germany) according to manufacturer’s
Immunomodulatory Effects of Interferon-a in CML
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NanoDrop (Thermo Scientific, Waltham, MA, USA). DNA was
stored at 220uC.
Detection and sequencing of TCR c- and d-gene
rearrangements by PCR
TCR c- and d-gene rearrangements were studied by PCR
analysis using 12 primer pairs for c-gene and 6 primer pairs for d-
genes detecting most of the known TCR c- and d-gene
rearrangements. The lower detection limit of the assay is 1–5%
of clonal cells among polyclonal lymphocytes. The analysis was
done according to the BIOMED-1 PCR protocol [25]. Clonal
products were identified by heteroduplex analysis, sequenced and
analyzed as described previously [26].
Design of individual allele-specific oligonucleotide (ASO)
primers and establishment of clones in different cell
populations with RQ-PCR
Patient-specific allele-specific oligonucleotide (ASO) primers for
real-time quantitative PCR (RQ-PCR) were designed as explained
previously [26]. Basically, the ASO primers were designed to
match the hypervariable junction regions of the sequenced TCR
d- and TCR c-gene rearrangements. TaqMan RQ-PCR was
performed using the ASO-primers together with a consensus
primer and a TaqMan probe, which were selected according to
the D- and J-gene present in the detected clonal rearrangement
(primer and probe sequences available from the authors upon
request). DNA from sorted cell populations or diagnostic phase















1. CML CP M 28 - 358 5 MU/3x weekly (1. year),
3 MU/3x weekly – cont.
MCyR Neg ND
2. CML CP F 63 - 63 4.5 MU/daily (1. year),
3 MU/3x weekly – cont.
MCyR Pos ND
3. CML CP F 45 - 160 5 MU/daily (1. year),
3 MU/3x weekly – cont.
CMR Neg ND
4. CML CP M 62 LR 144 auto-PBSCT
c,
1.5 MU/2x weekly – cont.
MMR Neg ND
5. CML CP F 35 LR 240 2 MU/3x weekly – cont. CMR Pos 0.6%
6. CML CP F 39 - 200 busulfan
d,
1.5 MU/2x weekly – cont.
MMR ND ND
7. CML CP M 29 - 163 4.5 MU/6x weekly – cont. CMR Pos 0.9%
8. CML CP F 21 - 148 mini-ICE, 3 MU/daily – cont. CMR Pos 3.9%
9. CML CP F 55 LR 102 3 MU/daily – cont. CCyR ND ND
10. CML CP M 58 LR 147 3 MU/daily – cont. CMR ND ND
11. CML CP M 44 LR 204 IFN-a (10 years),
7 years no therapy
CMR Pos 0.3%
12. CML CP M 53 LR 170 IFN-a (11 years),
3 years no therapy
CMR Neg ND
13. CML CP F 53 LR 134 auto-PBSCT
c, IFN-a (8 years),
3 years no therapy
CMR Pos 0.6%
14. CML CP M 59 LR 86 IFN-a (6 years),
2 years no therapy
CMR ND ND
15. CML CP M 42 LR 84 CML-8
e (5 years),
2 years no therapy
CMR ND ND
16. CML CP M 36 LR 112 auto-PBSCT
c, IFN-a (5 years),
4 years no therapy
CMR ND ND
17. CML CP F 41 LR 172 auto-PBSCT
c, IFN-a (7 years),
7 years no therapy
CMR ND ND
18. CML CP F 54 IR 168 IFN-a (9 years),
4 years no therapy
CMR Pos 0.9%
19. CML CP F 53 IR 152 IFN-a (8 years),
4 years no therapy
CMR ND ND
No, patient number; dg, diagnosis; CML; chronic myeloid leukemia; CP, chronic phase; auto-PBSCT, autologous peripheral blood stem cell transplantation; F, female; M,
male; IFN-a, interferon-a; IR, intermediate risk; LR, low risk; MCyR, major cytogenetic response, CCyR, complete cytogenetic response; CMR, complete molecular
response; MMR, major molecular response; cont, continues; HLA, human leukocyte antigen; PR1, a peptide for proteinase-3; ND, not done.
aAge at diagnosis;
bcourse of therapy; all patients were pretreated with hydroxyurea if not otherwise mentioned;
cauto-PBSCT, priming miniICE, conditioning high-dose busulfan;
dbusulfan sequential therapy regimen after pre-treatment with hydroxyurea;
eIFN-a administration in CML-8 protocol (combined with peroral cytarabine at the start);
fpercentage of PR-1 specific cells from CD8+ T-cells.
doi:10.1371/journal.pone.0023022.t001
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TaqMan Universal PCR Mastermix (Applied Biosystems).
Luminex assay of cytokines
The plasma of 10 healthy volunteers and patients treated with
IFN-a, including 19 CML patients and 4 control MPN patients,
were analyzed for following cytokines; interleukin-1b (IL-1b), IL-
1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-
13, IL-15, IL-17, TNF-a (tumor necrosis factor alpha), IFN-a
(interferon alpha), GM-CSF (granulocyte macrophage colony-
stimulating factor), MIP-1a (macrophage inflammatory protein 1a
/CCL3), MIP-1b (macrophage inflammatory protein 1b /CCL4),
IP-10 (IFN-inducible protein 10 /CXCL10), MIG (monokine
induced by interferon gamma /CXCL9), Eotaxin (CCL11),
Rantes (CCL5), MCP-1 (monocyte chemoattractant protein 1 /
CCL2), and IFN-c (interferon gamma) using a Human Cytokine
25-plex Panel (Invitrogen) accoring to the manufactorer’s
instructions. Measurement and analysis was performed in Bio-
Plex
TM 200 System (BioRad).
Statistical analysis
Statistics of the immunophenotyping results were done with
SPSS version 16.0. Assessment of the statistical significance of the
other experiments was done with GraphPrism (GraphPad
Software Inc., CA, USA). Cytokine profiles were analyzed with




All CML patients studied were in chronic phase. None of the
patients were treated with TKI therapy, or had undergone
allogeneic stem cell transplantation making this group of patients
rare and therefore limited. The median time on IFN-a therapy
was 11.8 years (range 5.3–19.3 years) in patients who were still on
treatment (IFN-ON) and 7.8 years (4.8–10.8) in patients who had
discontinued therapy (IFN-OFF, table 1). In IFN-OFF patients,
the median time without treatment before blood sampling was 4.4
years (2.0–8.0). Most (8/10) IFN-ON patients had at least CCyR
and 5 were in CMR. 2 patients had major cytogenetic response,
but the disease was stable and the treatment had continued for
more than 5 years in both patients. The IFN-a dose differed
markedly between patients ranging from 1.5 million units (MU)
twice weekly to 3 MU daily (table 1) mirroring well the real clinical
situation as the tolerated and effective dose of IFN-a varies greatly
between individual patients. 85% of patients (11 of 13) from whom
data was available belonged to low Sokal risk group and 15% to
intermediate risk group.
Increased amount of NK-cells in patients who have
successfully discontinued IFN-a therapy
Immunophenotyping of basic leukocyte subpopulations was
done with a multicolor flow cytometry panel. Median total
lymphocyte count did not differ significantly between healthy
controls (1.81610
9/l) and IFN-ON (1.52610
9/l) or IFN-OFF
patients (1.52610
9/l). The proportion of CD3
+ T-cells from total
lymphocyte population was decreased in both CML patient
groups when compared to healthy volunteers (67% in IFN-ON,
56% in IFN-OFF vs. 73% in healthy controls, p=0.0002)
(Figure 1A, Table S1). Similarly, the absolute T-cell numbers




9/l, respectively, p=0.0049) as well as the amount of
NKT-like cells (Table S1).
The proportion of NK-cells from total lymphocyte population
was significantly increased in the IFN-OFF group (26%) as
compared to IFN-ON group (12%) or to healthy controls (11%)
(Figure 1B, p=0.0005). Absolute NK-numbers differed similarly
with marked variation in the IFN-ON group of patients (Table
S1).
The CD4/CD8 ratio was lower in IFN-ON (1.3) and IFN-OFF
(0.8) groups in comparison to healthy volunteers (2.2, p=0.0402).
This predominantly reflected the higher proportion of cytotoxic
CD8
+ T-cells (44% of total T-cell population in IFN-ON, 55% in
IFN-OFF vs. 31% in healthy controls, p=0.0388, figure 1C,
Table S1). Furthermore, the absolute CD4+ T-cell numbers were
decreased both in IFN-ON (0.47610
9/l) and IFN-OFF (0.33
610
9/l) groups when compared to healthy controls (0.84610
9/l,
p=0.0010, Table S1). IFN-a treated MPN patients had
comparable numbers of NK-cells and CD8+ T-cells as healthy
controls (figure 1 B, C).
There was no difference in the proportion or absolute counts of
B-cells (Table S1). No significant difference was observed in the T-
cell receptor (TCR) subtype distribution between healthy volun-
teers and the IFN-a subgroups (Table S1).




We further examined the memory and activation status of T-
cells. Interestingly, both CML patient groups had significantly
larger proportion of CD45RO-positive T-cells, which are antigen
encountered memory cells (58% in IFN-ON group and 74% in
IFN-OFF group vs. 44% in healthy volunteers, p=0.0059)
(figure 1D, Table S1). No significant difference was observed in
the proportion of CD57 activation antigen expressing T-cells
(Table S1), but patients in the IFN-OFF group in particular had
proliferating CD3+ T-cells as assessed by Ki-67 antigen expression
(figure 1E).
Increased proportion of regulatory T-cells in IFN-a
treated CML patients
The median proportion of Tregs from CD4
+ lymphocytes was
significantly increased in IFN-OFF subgroup (6.1%) compared to
healthy volunteers (3.8%) and IFN-ON subgroup (5.2%)
(p=0.0114, Table S1). However, no difference was observed in
absolute Treg numbers (Table S1).
Immunoprofile stays stable in follow-up samples
From 7 patients (4 IFN-ON and 3 IFN-OFF) a follow-up sample
was available. The time between the first and second sample
varied from 15 to 31 months. The proportion of NK-cells was
stable over time and no significant variation was detected in the
values between 2 time-points (data not shown). Similarly, in other
cell types (CD8+ cells and CD45RO+ cells) in which significant
differences were observed between the study cohorts, the results
between 2 time-points did not differ markedly.
HLA-A2 and PR1 specific T-cells
To be able to analyze the proportion of PR1 specific T-cells,
patients’ HLA-A2 status was determined as PR1 MHC Class I
human tetramer antibody staining is restricted only to HLA-A2
positive patients. Suitable samples for HLA-A2 analysis were
available from 10 CML patients, and 7 were positive for HLA-
A*0201 (table 1). All these 7 patients had detectable PR1 specific
CD8+ T-cells with the proportion varying between 0.3% and
3.9% of total CD8
+ cell population (table 1).
Immunomodulatory Effects of Interferon-a in CML
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23022Figure 1. Flow cytometry analysis of basic lymphocyte subpopulations. Immunophenotyping was done with 6-color flow cytometry from
healthy controls (n=16), IFN-a-treated CML patients (IFN-ON, n=10), and CML patients who had discontinued IFN-a therapy (IFN-OFF, n=9). Figures
represent relative proportions of analyzed cells and corresponding absolute numbers can be found in Table S1. Statistical significance of differences
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patients
As our previous studies have shown that the majority of CML
patients have clonal lymphocytes already at the time of diagnosis
and that they expand during dasatinib (2
nd generation TKI)
therapy [26], we wanted to study the presence of clonal
lymphocytes in IFN-a treated patients. Clonality of the cells was
determined by using a sensitive TCR c/d rearrangement PCR
assay (sensitivity of the assay is 1% of clonal cells within the total
assayed cell population). 22 healthy volunteers were analyzed as
controls. In three healthy volunteers (14%), a clonal TCR c-
rearrangement was confirmed. However, no clonal TCR d-gene
rearrangements were detected in healthy controls (table 2). The
healthy individuals with clonal T-cells (male 44 years, male 33
years, and female 47 years) were asymptomatic and had normal
blood counts.
In contrast, 18 of 19 (95%) CML patients treated with IFN-a
had a clonal rearrangement in TCR c- and/or d-genes (table 2).
Both IFN-ON and IFN-OFF patients had frequently clonal TCR
c- (80% vs. 100%, respectively) and TCR d-gene rearrangements
(60% vs. 67%). In most patients more than one clonal TCR
rearrangement was confirmed (15 of 19; 79%). 2 of 4 (50%) MPN
patients included in this study had clonal TCR c- and TCR d-
gene rearrangements. In one CML patient and two MPN patients
(male 34 years and female 26 years) no clonal rearrangements
could be detected with the set of primers used in this study.
Two CML patients had a diagnostic phase sample available
(patients 9 and 18). Patient 18 showed no clonal lymphocytes at
Table 2. Sequence confirmed clonal TCR c- and d-gene rearrangements.
No. Patient group TCR delta primer pairs TCR gamma primer pairs




1 IFN-ON X X X X X
2 IFN-ON X X X X
3 IFN-ON
4 IFN-ON X X X X X X X




9 IFN-ON X X X
10 IFN-ON X X XX
11 IFN-OFF X X X X X X
12 IFN-OFF X X X X X
13 IFN-OFF X X X
14 IFN-OFF X X
15 IFN-OFF X X
16 IFN-OFF X
17 IFN-OFF X X
18 IFN-OFF X X
19 IFN-OFF X X X
20 MPN
21 MPN
22 MPN X X X X
23 MPN X X X X X
No refers to patient number in the Table 1; IFN-ON, CML patients with ongoing IFN-a therapy; IFN-OFF, CML patients who have discontinued the therapy; MPN
myeloproliferative neoplasm.
Clonality was determined by PCR and gel analysis using 12 primer pairs for the TCR c-gene rearrangements and 6 primer pairs for TCR d-gene rearrangements. Positive
clonal PCR products were confirmed with sequencing and are marked in the columns as X. Clonal TRGV9*01 / TRGJP*01 rearrangements are marked with bold and italic.
doi:10.1371/journal.pone.0023022.t002
in continuous variables was assessed by a non-parametric analysis of variance using the Kruskal-Wallis test (P-values reported in figures) and in case
of a significant main effect, pairwise comparisons of patient groups were calculated using Dunn’s multiple comparison test (statistically significant
differences between groups are marked with asterisks and line). For the analysis of Vc9
+ cells (panel F), samples from 5 healthy controls, 4 IFN-ON,
and 5 IFN-OFF patients were available. The figures also include results from four patients with myeloproliferative neoplasm (MPN), but they were not
included in the statistical analysis.
doi:10.1371/journal.pone.0023022.g001
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primer pair TCR gamma 10 (table 2). A clone could be detected
with the same pair 8 years later during IFN-a therapy, but the
junction region sequence varied slightly suggesting that the clone
was not identical or it has evolved during the years.
A unique pattern of TCR c/d rearrangements is observed
in IFN-a treated patients
Surprisingly, in the majority of CML patients either on IFN-a
therapy (70%) or who had been able to discontinue the therapy
(78%), a clonal rearrangement was detected with the same primer
pair Vg2-Jg1.2 (table 2, TCR c primer pair 5). Also 2/4 MPN
control patients had a clone detected with this pair of primers.
However, no similarities could be found in the specific junction
regions (Table S2).
A similar finding was observed in TCR d-gene rearrangements
detected with primer pairs 1 and 3 (Vd1-Jd1 and Vd2-Jd1, both
generating complete rearrangements, table 2). 9 of 14 CML
patients (64%) who had a rearrangement detected with Vg2-Jg1.2
had also a clone detected with Vd1-Jd1 and/or Vd2-Jd1 (table 2).
Also the two MPN patients had the both TCR genes rearranged.
Similarly, no pattern could be found in the specific junction
regions (Table S3).
The same unique pattern has not been observed earlier in TKI-
treated patients [26] and was not either seen in healthy volunteers
(1 positive finding in 47 years old female of total 22 volunteers
studied).
Clonal TCR c- and d-gene rearrangements are found in
the cd
+ T-cell population
To further elucidate in which cell population the clonal cells
resided, PB MNC from 8 CML and 2 MPN control patients





+ T-cell populations. For 3 patients, patient specific
(ASO)-primers were designed for the detection of clonal TCR c-
and d-gene rearrangements (Table S2 and S3) and for the rest of
the patients (n=5) above described PCR protocol was used to
detect the site of the clonal population. In all CML and MPN
patients, a clonal TCR c/d rearrangement was observed within
CD3
+ cd
+ T-cell population. Example of one patient is shown in
figure 2. ab+ T-cell populations were negative with corresponding
primers.
To be able to see if these specific clonal TCR c- and d-gene
rearrangements were present in small quantities also in the cd
+ T-
cell population in healthy controls, we enriched cd
+ T-cells from 3
healthy volunteers by FACS. One healthy control showed a clonal
population. Of note, the clone was only detected in the purified
cd
+ T-cell population; PCR done from MNC showed no clonal
product indicating that the amount of cd
+ T-cell clone is less than
1% from the total MNC. In contrast, in CML patients the clone
was detected also in the whole MNC population. However, most
of the clones (confirmed by sequencing) were detected against a
strong polyclonal background, indicating that majority of cd
+ T-
cells are polyclonal.
Increased amount of Vc9
+ cells in patients who had
discontinued IFN-a therapy
As the majority of IFN-a treated patients had a distinct clonal
rearrangement detected with the same primer pair Vg2-Jg1.2 in
the cd
+ T-cell populations and as it has previously been described
that this primer pair recognizes Vd2Jc9 T-cells [27], we wanted to
analyze the proportion of Vc9
+ cells in CML (n=9) and MPN
(n=3) patients and in healthy controls (n=5). The majority of cd
+
T-cells both in patients and in healthy controls were Vc9
+ cells
(median percentages for healthy 78%, IFN-ON 57%, and MPN
patients treated with IFN-a 62%)(figure 1F). Especially in patients
who had discontinued the therapy, nearly all (median percentage
92%) cd
+ T-cells were Vc9
+ cells (figure 1F).
CML patients treated with IFN-a have a distinct cytokine
profile compared to healthy volunteers
Plasma cytokine levels were analyzed with a multiplex bead-
based cytokine assay assay (LuminexH) measuring 25 different
cytokines. IP-10 (CXCL10), IL-6, IL-12, and MCP-1 (CCL2)
levels were significantly increased IFN-ON patients when
compared with healthy controls (figure 3). As it is known that
IFN-a therapy can induce most of these factors [28], it was
interesting to observe that also patients who had discontinued
IFN-a therapy over 2 years prior to sample collection had higher
IL-6, IL-12, IP-10, eotaxin (CCL11), and MCP-1 levels when
compared to healthy controls (comparisons between 2 groups were
done with Mann-Whitney U-test). Especially plasma eotaxin levels
were markedly increased in IFN-OFF group compared to healthy
volunteers (1173 and 427.7 pg/ml, respectively; p,0.0001).
However, no differences in eosinophil counts were detected (data
not shown). Similarly, MCP-1 levels differed markedly between
these 2 groups (631.5 vs. 106.5 pg/ml, p=0.0003) but no
differences in monocyte counts were observed (data not shown).
In 4 MPN control patients treated with IFN-a, plasma eotaxin
and MCP-1 levels were at the same range as in healthy volunteers
(figure 3D–E).
Figure 2. Clonal Vc9 rearrangement in cd
+ T-cells. Example of
Vd2Jc9 clonality detection in patient number 4 (Table 1). PCR with Vg2-
Jg1.2 primers was carried out on FACS sorted cell fractions and the
clonal products were identified by heteroduplex analysis. Lane 1, DNA
ladder; lane 2 ab
+ T-cell fraction; lane 3 cd
+ T-cell fraction; lane 4 pool of
healthy controls showing polyclonal smear; lane 5, water control. Clonal
PCR product in the cd
+ T-cell fraction is shown with a white arrow.
doi:10.1371/journal.pone.0023022.g002
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receptors for eotaxin and MCP-1
To examine if cd
+ and ab
+ T-cells have corresponding
receptors (CCR2 and CCR3) for the cytokines (MCP-1 and
eotaxin, respectively) which were increased in both CML groups,
samples from IFN-ON (n=4), IFN-OFF (n=3), MPN control
patients (n=3), and healthy volunteers (n=5) were analyzed with
flow cytometry. Both T-cell subsets in all study groups expressed
these receptors, although the proportion of CCR2 and CCR3
positive cells were low (0.1%–8.0% of cd
+ and ab
+ T-cells).
Possible factors predicting persistent leukemia dormancy
after IFN-a discontinuation
Based on previous studies in patients with prolonged complete
remission on IFN-a therapy [23,24], we estimated that approx-
imately 50% of our IFN-ON patients could discontinue IFN-a
without imminent disease relapse. Therefore, we were interested to
see if it would be possible to find markers that could be used in
predicting which patients will relapse after IFN-a discontinuation
and which will remain in remission and in the state of leukemia
dormancy. A hypothetical variable, which would predict in the
IFN-ON group which patients can stop IFN-a, would need to
fulfill at least the following criteria: (1) IFN-ON median values of
the variable should be significantly different (higher or lower) from
IFN-OFF values and (2) IFN-ON values of the variable should
have approximately twice the variance of IFN-OFF values
(figure 4A).
After review of all the immunological variables analyzed in the
present study, both NK cell proportion from lymphocytes and
absolute NK-cell count best fulfilled the criteria for a predictor
variable for drug discontinuation. To characterize the IFN-ON
cohort in more detail we next divided the IFN-ON cohort into two
subgroups based on the median NK-cell count of 0.2610
9/L: the
high NK group (NK-cell count.0.2) constituting patients most
likely to remain in remission after IFN-a discontinuation, and the
low NK group (,0.2) (figure 4B).
There were no evident differences in the high or low NK
groups with regards to gender, duration of disease or IFN-a dose




+ T-cells and lower CD4/CD8 ratio was observed in the
IFN-ON NK high and INF-OFF groups as compared to IFN-ON
NK low group (figure 4C–F). Clonal cd
+ T-cells were more often
observed in the IFN-ON NK high (100%) and INF-OFF (75%)
groups as compared to IFN-ON NK low group (40%). Interes-
tingly, IP-10 levels were lower in the IFN-OFF as compared to the
IFN-ON NK low group with IFN-ON NK high patients showing
values in between (figure 4H). No differences in plasma eotaxin
levels were observed (figure 4G). However, the number of patients
is small and confirmatory studies with larger patient populations
are warranted.
Discussion
CML is considered to be one of the most susceptible
malignancies to immune manipulation. Results from allogeneic
Figure 3. Plasma IP-10, IL-6, IL-12, eotaxin, MCP-1, and IFN-c cytokine levels. Plasma levels of 25 cytokines were measured with a multiplex
bead-based cytokine assay (LuminexH) from healthy controls (n=10), IFN-a-treated CML patients (IFN-ON, n=10), and CML patients who had
discontinued IFN-a therapy (IFN-OFF, n=9). Statistical significance of differences in continuous variables was assessed by a non-parametric analysis of
variance using the Kruskal-Wallis test (P-values reported in figures) and in case of a significant main effect, pairwise comparisons of patient groups
were calculated using Dunn’s multiple comparison test (statistically significant differences between groups are marked with asterisks and line). The
figures also include results from four patients with myeloproliferative neoplasm (MPN), but they were not included in the statistical analysis.
doi:10.1371/journal.pone.0023022.g003
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infusion therapies have shown remarkable, curative anti-leukemia
effects mediated by alloreactive cytotoxic lymphocytes [29].
Encouraging data from clinical trials with BCR-ABL1 peptide
vaccines confirm the clinical usefulness of provoking anti-CML
immune responses [30,31]. Several groups have recently reported
a favorable outcome for CML patients treated with imatinib in
combination with IFN-a, compared to patients on imatinib
monotherapy [9,10,11] Furthermore, IFN-a therapy may increase
the likelihood to stop treatment without relapse [5,12]. Most
patients who have successfully discontinued the therapy, still have
detectable minimal residual disease, but the disease is stable and
does not progress [23,24]. This implies that IFN-a therapy has
induced an immune response with currently unknown mecha-
nisms, which is able to keep tumor cells dormant.
In this study, we focused on determining the immunomodula-
tory effects of IFN-a in patients who had used the drug as
monotherapy with an excellent treatment response. As TKIs
currently have substituted IFN-a as a first line therapy, this group
of patients is quite unique. The heterogeneity of the studied patient
population considering IFN-a dose and treatment duration as well
as reasons why patients have stopped the treatment needs to be
taken into account when evaluating these results, but they also
represent well the real clinical situation. The tolerated and
effective dose of IFN-a varies greatly between individual patients.
However, a common denominator in our patient cohort is the long
lasting response to therapy, which can usually be achieved only in
a small minority of IFN-a treated patients. The IFN-a treatment
duration (median 11.8 years in IFN-ON group and 7.8 years in
IFN-OFF group) is also considerably long as well as time without
any treatment in IFN-OFF group (4.4 years) and therefore it is
unlikely that the possible earlier autologous transplantation plays a
major role in this setting.
Despite these limitations in the patient number, we were able to
recognize distinct factors correlated with prolonged IFN-a therapy
response even after discontinuation of the drug. One of these
factors was a shift in the lymphocyte profile in IFN-a treated
patients into a more cytotoxic direction. Significant increase of
CD8
+ T-cells was observed in CML patients who were still on
IFN-a therapy. In patients, who had been able to discontinue
therapy, the NK-cell counts were significantly higher. From a
proportion of patients we were able to analyze follow-up samples
taken .12 months interval from the first sample and importantly,
there was not significant intra-individual variation in immuno-
profile between different time points. Both CD8
+ T-cells and NK-
cells display cytotoxic effects on leukemia cells, which may play a
role in tumor surveillance. In CML, CD8
+ T-cells have been
reported to recognize leukemic cells [32]. Furthermore, NK-cells
have been shown to be able to kill CD34
+ CML stem cells, which
also may play a role in the graft vs. leukemia effect after allogeneic
transplantation [33],[34]. Of note, in our previous studies with
TKI treated patients, no increase of NK- or CD8
+ T-cells was
observed in imatinib treated patients [35]. Interestingly though, a
proportion of dasatinib treated patients developed expansion of
CD8
+ T-cells and/or NK-cells [35,36], which was associated with
superior therapy responses [36].
A number of previous studies have implicated that PR1 (a
peptide for proteinase-3) is an important tumor antigen for CTL
immune response against CML and that specific anti-PR1 T-cells
are involved in the elimination of CML cells [37,38]. In addition,
it has been suggested that induction of a PR1-specific CTL
response by IFN-a may contribute to improved molecular
response in patients treated with imatinib+IFN-a, and that these
patients could discontinue imatinib and continue IFN-a without
relapse [12]. PR-1 specific CTLs have also been reported to persist
in patients who do not relapse after IFN-a withdrawal [39]. In
concord, patients in our cohort also had PR1 specific T-cells
detectable in small quantities. No clear differences were found in
their amount between patients who were still on IFN-a treatment
or who had discontinued the therapy, but this could be also due to
small patient number studied.
As our previous report showed that oligoclonal, Ph-chromo-
some negative lymphocytes are common in CML patients at
diagnosis and during TKI therapy, we hypothesized that these
cells could also be found in IFN-a treated patients. Indeed, clonal
lymphocytes were observed in most (95%) IFN-a treated CML
patients. Strikingly, and in contrast to TKI-treated patients or
healthy controls, a unique rearrangement pattern was observed in
IFN-a treated CML patients. A total of 79% of the patients had a
clonal rearrangement detected with the same primer pair (Vg2-
Jg1.2) whereas during TKI therapy only 10–20% of the patients
displayed similar rearrangement [26] suggesting that this phe-
nomenon was associated with IFN-a therapy. It is however
uncertain whether this similar rearrangement pattern could be a
consequence of same antigen recognition, as no similarities could
be found in the specific junction region. Interestingly though,
further characterization of the cell populations revealed that the
clonal cells resided only in cd
+ T-cell population. It is believed that
cd T-cell responses are driven more by imbalance in the host (e.g.
cell transformation and inflammation) than by specific pathogen
challenges, which could explain that there were no similarities in
the junction regions. One hypothesis propose that these cells can
directly recognize antigens in the tissue, including ‘‘stress antigens’’
that are markers of cell infection or transformation [40]. The role
of cd
+ T-cells in tumor immunology has been disputable, and
there are only few reports of their importance in hematology [41].
In myeloma patients, activated Vc9Vd2 cells were able to kill
malignant plasma cells [42]. Also in acute leukemia, it has been
reported that Vc9Vd2 cells are increased, and that they are related
to better disease-free survival after bone marrow transplantation
[42]. In addition, one recent report in CML showed that ex vivo
expanded cd
+ T-cells were able to kill K562 cells [43]. Our results
show for the first time that significant amounts of clonal cd
+ T-
cells exist in CML patients who can be considered to be cured
(patients without the treatment) which suggests that these cells
possess protective, anti-leukemic properties in vivo in patients.
Cytokines are important mediators of immune cell signaling and
chemokines (chemotactic cytokines) induce directed chemotaxis in
nearby responsive cells. In our patient cohort we noticed that
levels of several cytokines and chemokines (IL-6, IL-12, IP-10,
eotaxin, MCP-1, and IFN-c) were increased in CML patients
treated with IFN-a. IFN-a therapy itself may increase plasma
Figure 4. Characteristics of a predictor variable for IFN-a discontinuation. A. Example of a hypothetical variable differentiating patients who
can stop IFN-a therapy (empty circle) from those who cannot in the IFN-ON group. B. NK-cell count as a potential predictor variable. The figure
presents absolute NK-cell numbers in different patient groups. Patients still using IFN-a therapy were divided in 2 groups based if their absolute NK-
cell count was above (IFN-ON NK-high) or below (IFN-OFF NK-low) 0.2610
9/l. C–H. Biomarker profile of NK-high and NK-low groups. Patients using
IFN-a therapy (IFN-ON) were divided in 2 groups based on the absolute NK-cell count in the peripheral blood. In NK-high group, the absolute NK-cell
count was above 0.2610
9/l and in NK-low group below the given limit. Other variables are presented based on the group division by NK-cell number
and IFN discontinued patients as a separate cohort (IFN-OFF).
doi:10.1371/journal.pone.0023022.g004
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interestingly, it remained at higher level in the IFN-a discontinued
subgroup as well. Saudemont et al have earlier shown that IP-10
provides protection against leukemia in mice. Mice vaccinated or
treated with IP-10 transduced cell lines survived leukemia
significantly better than controls, which was explained by
increased percentage of NK cells, activation of NK cells and
improved cytotoxicity of these cells [44]. These results are in
accordance with our results and IP-10 could provide an additional
mechanism of elimination of dormant tumor cells [44].
Especially eotaxin and MCP-1 levels were higher in the IFN-a
discontinued subgroup as compared to healthy volunteers. The
same trend was not seen in the control MPN patients included in
this study or in CML patients treated with dasatinib or imatinib
(A. Kreutzman, unpublished observations). Increased plasma
levels of MCP-1 (CCL2) signify the activation of Th1 type
immune response, whereas the presence of eotaxin (CCL11) is an
indication of Th2 type response. In line with this dichotomy,
patients continuing IFN-a therapy tend to have higher MCP-1
levels than patients who had discontinued therapy. Furthermore,
patients who had discontinued the therapy had higher eotaxin
levels, which may indicate a switch to a Th2 type response. Both of
these cytokines have been related to outcome of cancer patients.
Eosinophils secrete eotaxin in response to tumors [45] and high
MCP-1 levels are associated with a more favorable prognosis in
pancreatic cancer [46]. Our results also confirmed that cd
+ T-cells
in IFN-a treated CML patients expressed corresponding cytokine
receptors (CCR2/MCP-1 and CCR3/eotaxin).
There is a growing interest to find biomarkers predicting which
patients could stop IFN-a or TKI therapy without disease relapse.
A recent case report suggested that patients who were able to
discontinue IFN-a treatment, had an increased amount of
CD8
+CD45RO
+ memory cells compared to patients who relapsed
after imatinib or IFN-a discontinuation [47]. Accordingly, in our
limited material, we observed elevated numbers of CD45RO
+
CD3
+ T-cells especially in the IFN-a discontinuation subgroup.
Similarly, in dasatinib treated CML patients we have earlier
reported that majority of CD8
+ T-cells are CD45RO
+ [35] and
this phenotype is related to better therapy outcome [26,36].
Mahon et al has recently reported that patients who discontinued
imatinib treatment without disease relapse belonged more often to
Sokal low risk group and had increased numbers of NK-cells at the
time of discontinuation (Mahon FX et al. Blood 2009 114:
Abstract 859). Similarly, in our IFN-a cohort, 85% of the patients
had low Sokal risk, and absolute and relative NK-cell numbers
seem to divide patients into 2 different groups. All patients who
had been able to discontinue the therapy had NK-cell counts
above 0.2610
9/L, whereas approximately half of the patients who
still used IFN-a therapy had values less than 0.2610
9/L.
Interestingly, patients in NK-high group also had more often
RO+ T-cells and clonal Vg9 cells thus further refining the
predictive immunoprofile. The biomarker profile described in this
paper could be a candidate profile when considering which
patients can discontinue the IFN-a treatment without imminent
disease relapse, yet the patient population studied is small.
Prospective clinical trials are needed to confirm its usefulness in
decision-making.
Taken together, our results show that IFN-a treatment induces
distinct changes in the immunoprofile of CML patients, which
may contribute to prolonged therapy responses in this unique
group of patients. The potent immunomodulatory effects observed
imply that IFN-a still may have a role in the future therapy
protocols aiming in permanent cure of CML.
Supporting Information
Table S1 Lymphocyte subpopulations analyzed with
flow cytometry. PB, peripheral blood; IFN-ON, CML patients
with ongoing IFN-a therapy; IFN-OFF, CML patients who have
discontinued the therapy
aContinuous variables are expressed as
median (minimum-maximum).
bStatistical significance of differ-
ence is evaluated by non-parametric Kruskal-Wallis test.
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Table S2 TCR c-gene sequences of clonal lymphocyte
populations detected with TCR c primer pair 5. The table
presents detected TCR c rearrangements with TCR-c primer pair
5 (table 3). Sequences of the junction are aligned. No refers to
patient number in Table 2.
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Table S3 TCR d-gene sequences of clonal lymphocyte
populations detected with TCR d primer pair 3. The table
presents detected TCR d rearrangements. Sequences of the
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